Compare Match Group Inc (MTCH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Match Group Inc trades at $36.46 (market cap $8.45B), while State Street SPDR S&P Biotech ETF trades at $159.17. The key difference: Match Group Inc pays a 2.17% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Match Group Inc nearer its low. Which is the better fit depends on your goals.
| MTCH | XBI | |
|---|---|---|
Market Cap | $8.45B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $41.24 | $164.28 |
52-Week Low | $28.90 | $86.92 |
Enterprise Value | $11.42B | — |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Match Group (MTCH) trades at $36.36, down 1.01% on the day, with a bearish technical signal but neutral oscillators. The company reported mixed Q2 2026 results, missing revenue estimates but beating EPS, with Tinder showing engagement improvements and Hinge growing revenue 22% year-over-year. Financials indicate strong profitability with a net income margin of 20.17% and a P/E ratio of 13.05, while cash flow trends show positive net cash flow in 2025. Recent news highlights institutional buying and Zacks rankings for growth, income, and value stocks.
The outlook for MTCH is cautiously optimistic, with analyst consensus pointing to a $42.33 price target and no sell ratings. Risks include Tinder's sluggish performance and high debt levels, but opportunities lie in Hinge's expansion and product innovation. Investors should weigh solid fundamentals against competitive and execution risks in the dating app market.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
